The Alimentary Tract and Metabolism Medicine Sales in Canada demonstrated consistent growth from 2023 through 2028. In 2023, the sales stood at $6.25 billion USD PPP. Forecasted figures indicate gradual increases each year, reaching $9.5 billion USD PPP by 2028. Year-on-year, the sales are expected to grow by 9.6% in 2024, 9.6% in 2025, 8.9% in 2026, 7.9% in 2027, and 7.5% in 2028. The Compound Annual Growth Rate (CAGR) from 2024 to 2028 is estimated at 8.7%.
In the coming years, trends to watch include the potential impact of new drug innovations, changes in healthcare policies, and the aging population in Canada, which is likely to drive demand for medications addressing metabolic and digestive health issues.